MedKoo Cat#: 526393 | Name: FKGK11
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FKGK11 is a novel potent inhibitor of GVIA iPLA2 with little or no inhibition against GIVA cPLA2 (XI(50) = 0.0073 and >0.91, respectively).

Chemical Structure

FKGK11
CAS#1071000-98-0

Theoretical Analysis

MedKoo Cat#: 526393

Name: FKGK11

CAS#: 1071000-98-0

Chemical Formula: C13H13F5O

Exact Mass: 280.0887

Molecular Weight: 280.24

Elemental Analysis: C, 55.72; H, 4.68; F, 33.90; O, 5.71

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
FKGK11; FKGK 11; FKGK-11
IUPAC/Chemical Name
1,1,1,2,2-Pentafluoro-7-phenyl-heptan-3-one
InChi Key
ROPVXAWEVYWEQY-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H13F5O/c14-12(15,13(16,17)18)11(19)9-5-4-8-10-6-2-1-3-7-10/h1-3,6-7H,4-5,8-9H2
SMILES Code
O=C(CCCCC1=CC=CC=C1)C(F)(F)C(F)(F)F
Appearance
A solution in ethanol
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 280.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Paliege A, Roeschel T, Neymeyer H, Seidel S, Kahl T, Daigeler AL, Mutig K, Mrowka R, Ferreri NR, Wilson BS, Himmerkus N, Bleich M, Bachmann S. Group VIA phospholipase A2 is a target for vasopressin signaling in the thick ascending limb. Am J Physiol Renal Physiol. 2012 Apr 1;302(7):F865-74. doi: 10.1152/ajprenal.00222.2011. Epub 2012 Jan 4. PubMed PMID: 22218592. 2: Li H, Zhao Z, Antalis C, Zhao Z, Emerson R, Wei G, Zhang S, Zhang ZY, Xu Y. Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development. Am J Pathol. 2011 Jul;179(1):452-61. doi: 10.1016/j.ajpath.2011.03.027. Epub 2011 May 17. PubMed PMID: 21703423; PubMed Central PMCID: PMC3123860. 3: Kalyvas A, Baskakis C, Magrioti V, Constantinou-Kokotou V, Stephens D, López-Vales R, Lu JQ, Yong VW, Dennis EA, Kokotos G, David S. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain. 2009 May;132(Pt 5):1221-35. doi: 10.1093/brain/awp002. Epub 2009 Feb 13. PubMed PMID: 19218359; PubMed Central PMCID: PMC2677793. 4: Baskakis C, Magrioti V, Cotton N, Stephens D, Constantinou-Kokotou V, Dennis EA, Kokotos G. Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. doi: 10.1021/jm800649q. PubMed PMID: 19053783; PubMed Central PMCID: PMC2649009. 5: López-Vales R, Navarro X, Shimizu T, Baskakis C, Kokotos G, Constantinou-Kokotou V, Stephens D, Dennis EA, David S. Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131(Pt 10):2620-31. doi: 10.1093/brain/awn188. Epub 2008 Aug 21. Erratum in: Brain. 2010 Nov;133(11):3485. PubMed PMID: 18718965; PubMed Central PMCID: PMC2860706.